NCT07095270 is a NA clinical trial of Circadian OS software in Circadian Disruption, sponsored by Icahn School of Medicine at Mount Sinai.

Who is sponsoring NCT07095270?

NCT07095270 is sponsored by Icahn School of Medicine at Mount Sinai.

What drugs are being tested in NCT07095270?

Interventions in NCT07095270: Circadian OS software.

What condition does NCT07095270 study?

NCT07095270 studies Circadian Disruption.

Is NCT07095270 still recruiting?

NCT07095270 is currently completed. Last updated 15 January 2026.

Last reviewed 2026-01-15 · How we verify

NCT07095270

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Circadian OS Technology on Melatonin Suppression

Completed NA Last updated 15 January 2026

What this trial tests

NA trial testing Circadian OS software in Circadian Disruption in 10 participants. Completed in 31 December 2025.

Timeline

7 July 2025

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	10
Start date	7 July 2025
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across United States

Drugs / interventions tested

Circadian OS software

Conditions studied

Circadian Disruption — all drugs for Circadian Disruption →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Adults 30 to 75, any sex, with Circadian Disruption. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Objective: Evaluate how the Circadian OS iPad-based light intervention suppresses melatonin. This small pilot study is designed to validate the Circadian OS technology by testing physiological response using melatonin suppression. The study aims to evaluate how the Circadian OS iPad-based light intervention influences sleepiness as measured objectively via suppression of melatonin and subjectively via the Karolinska Sleepiness scale.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07095270 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 15 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07095270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing